New Two-Drug attack on aggressive breast cancer
NCT ID NCT07244874
Summary
This study is testing whether combining two drugs, sacituzumab tirumotecan and toripalimab, can help control advanced triple-negative breast cancer that has spread and cannot be removed by surgery. It will involve about 41 women who have not yet received treatment for their advanced disease and whose tumors test positive for a specific marker called PD-L1. The main goal is to see how well the combination shrinks tumors and how safe it is for patients.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TNBC, TRIPLE NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.